Literature DB >> 17976158

Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis.

Hisamitsu Miyaaki1, Tatsuki Ichikawa, Kazuhiko Nakao, Hiroshi Yatsuhashi, Ryuji Furukawa, Kazuo Ohba, Katsuhisa Omagari, Yukio Kusumoto, Kenji Yanagi, Osami Inoue, Noboru Kinoshita, Hiromi Ishibashi, Michitami Yano, Katsumi Eguchi.   

Abstract

BACKGROUND/AIMS: We evaluated patients with nonalcoholic fatty liver disease (NAFLD) and compared the clinical and pathological features to identify the risk factors for NAFLD with severe fibrosis.
METHODS: One hundred and eighty-two patients with biopsy-confirmed NAFLD from various medical centres were recruited into this study.
RESULTS: The variables that were significantly associated with severe steatosis were male gender (mild:severe=36%:53%, P=0.02), younger age (mild:severe=57%:82%, P>0.001) and absence of type 2 diabetes (mild:severe=43%:71%, P>0.001). There was no significant difference in the degree of inflammation among the clinical groups. The variables that were significantly associated with severe fibrosis were female gender (mild:severe=54%:84%, P=0.002), older age (> or = 60 years old) (mild:severe=29%:53%, P=0.020), type 2 diabetes (mild:severe=42%:71%, P=0.020) and hypertension (mild:severe=24%:53%, P=0.002). Although there were more obese patients in the group with severe fibrosis, the association was not statistically significant (mild:severe=67%:78%, P=0.229). The prevalence of high serum triglyceride levels was similar between the two groups. The N (Nippon) score (total number of risk factor) could significantly predict severe fibrosis in NAFLD patients (1.48 +/- 1.14 vs. 2.66 +/- 0.94, P<0.001).
CONCLUSIONS: The N score can be used to predict severe fibrosis in cases of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17976158     DOI: 10.1111/j.1478-3231.2007.01614.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  25 in total

1.  Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.

Authors:  Anisha A Gupte; Joey Z Liu; Yuelan Ren; Laurie J Minze; Jessica R Wiles; Alan R Collins; Christopher J Lyon; Domenico Pratico; Milton J Finegold; Stephen T Wong; Paul Webb; John D Baxter; David D Moore; Willa A Hsueh
Journal:  Hepatology       Date:  2010-10-11       Impact factor: 17.425

2.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

3.  Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.

Authors:  Takaomi Kessoku; Yuji Ogawa; Masato Yoneda; Kento Imajo; Yoshio Sumida; Yuichiro Eguchi; Hideki Fujii; Hideyuki Hyogo; Masafumi Ono; Yasuaki Suzuki; Takumi Kawaguchi; Kazuaki Chayama; Saiyu Tanaka; Kazuma Fujimoto; Keizo Anzai; Toshiji Saibara; Michio Sata; Yoshito Itoh; Atsushi Nakajima; Takeshi Okanoue
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 4.  Can NASH be diagnosed, graded, and staged noninvasively?

Authors:  Garfield A Grandison; Paul Angulo
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

Review 5.  Nonalcoholic fatty liver disease and aging: epidemiology to management.

Authors:  Marco Bertolotti; Amedeo Lonardo; Chiara Mussi; Enrica Baldelli; Elisa Pellegrini; Stefano Ballestri; Dante Romagnoli; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 6.  Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease.

Authors:  Hisamitsu Miyaaki; Kazuhiko Nakao
Journal:  Clin J Gastroenterol       Date:  2017-03-13

7.  Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis.

Authors:  Huseyin Kayadibi; Mustafa Gültepe; Bulent Yasar; Ali T Ince; Omer Ozcan; Osman M Ipcioglu; Oya O Kurdas; Burhanettin Bolat; Yusuf Z Benek; Hakan Guveli; Sacide Atalay; Selvinaz Ozkara; Ozcan Keskin
Journal:  Dig Dis Sci       Date:  2008-11-07       Impact factor: 3.199

8.  Usefulness of ultrasonographic estimation of preperitoneal and subcutaneous fat thickness in the diagnosis of nonalcoholic fatty liver disease in diabetic patients.

Authors:  Kazuto Fukuda; Yasushi Seki; Masahiro Ichihi; Takuya Okada; Ayumu Hirata; Sachiyo Kogita; Yoshiyuki Sawai; Takumi Igura; Mamiko Tsugawa; Yasuharu Imai
Journal:  J Med Ultrason (2001)       Date:  2015-02-11       Impact factor: 1.314

9.  Alanine aminotransferase decreases with age: the Rancho Bernardo Study.

Authors:  Mamie H Dong; Ricki Bettencourt; Elizabeth Barrett-Connor; Rohit Loomba
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

10.  Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus.

Authors:  Toshihide Shima; Hirofumi Uto; Kohjiro Ueki; Toshinari Takamura; Yutaka Kohgo; Sumio Kawata; Kohichiroh Yasui; Hyohun Park; Naoto Nakamura; Tatsuaki Nakatou; Nobuyoshi Tanaka; Atsushi Umemura; Masayuki Mizuno; Junko Tanaka; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2012-08-22       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.